PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2017-18 Influenza Season.

Abstract This report updates the 2016-17 recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding the use of seasonal influenza vaccines (MMWR Recomm Rep 2016;65[No. RR-5]). Routine annual influenza vaccination is recommended for all persons aged ≥6 months who do not have contraindications. A licensed, recommended, and age-appropriate vaccine should be used.For the 2017-18 season, quadrivalent and trivalent influenza vaccines will be available. Inactivated influenza vaccines (IIVs) will be available in trivalent (IIV3) and quadrivalent (IIV4) formulations. Recombinant influenza vaccine (RIV) will be available in trivalent (RIV3) and quadrivalent (RIV4) formulations. Live attenuated influenza vaccine (LAIV4) is not recommended for use during the 2017-18 season due to concerns about its effectiveness against (H1N1)pdm09 viruses during the 2013-14 and 2015-16 seasons. Recommendations for different vaccine types and specific populations are discussed. No preferential recommendation is made for one influenza vaccine product over another for persons for whom more than one licensed, recommended product is available.Updates to the recommendations described in this report reflect discussions during public meetings of ACIP held on October 20, 2016; February 22, 2017; and June 21, 2017. New and updated information in this report includes the following:•Vaccine viruses included in the 2017-18 U.S. trivalent influenza vaccines will be an A/Michigan/45/2015 (H1N1)pdm09-like virus, an A/Hong Kong/4801/2014 (H3N2)-like virus, and a B/Brisbane/60/2008-like virus (Victoria lineage). Quadrivalent influenza vaccines will contain these three viruses and an additional influenza B vaccine virus, a B/Phuket/3073/2013-like virus (Yamagata lineage).• Information on recent licensures and labelling changes is discussed, including licensure of Afluria Quadrivalent (IIV4; Seqirus, Parkville, Victoria, Australia); Flublok Quadrivalent (RIV4; Protein Sciences, Meriden, Connecticut); and expansion of the age indication for FluLaval Quadrivalent (IIV4; ID Biomedical Corporation of Quebec, Quebec City, Quebec, Canada), previously licensed for ≥3 years, to ≥6 months.• Pregnant women may receive any licensed, recommended, age-appropriate influenza vaccine.• Afluria (IIV3; Seqirus, Parkville, Victoria, Australia) may be used for persons aged ≥5 years, consistent with Food and Drug Administration-approved labeling.• FluMist Quadrivalent (LAIV4; MedImmune, Gaithersburg, Maryland) should not be used during the 2017-18 season due to concerns about its effectiveness against influenza A(H1N1)pdm09 viruses in the United States during the 2013-14 and 2015-16 influenza seasons.This report focuses on the recommendations for use of vaccines for the prevention and control of influenza during the 2017-18 season in the United States. A Background Document containing further information and a summary of these recommendations are available at https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html. These recommendations apply to licensed influenza vaccines used within Food and Drug Administration-licensed indications, including those licensed after the publication date of this report. Updates and other information are available at CDC's influenza website (https://www.cdc.gov/flu). Vaccination and health care providers should check CDC's influenza website periodically for additional information.
PMID
Related Publications

Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007.

Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009.

Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010.

Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices--United States, 2013-2014.

Prevention and Control of Seasonal Influenza with Vaccines.

Authors

Mayor MeshTerms
Keywords
Journal Title mmwr. recommendations and reports : morbidity and mortality weekly report. recommendations and reports
Publication Year Start




PMID- 28841201
OWN - NLM
STAT- MEDLINE
DA  - 20170825
DCOM- 20170828
LR  - 20170828
IS  - 1545-8601 (Electronic)
IS  - 1057-5987 (Linking)
VI  - 66
IP  - 2
DP  - 2017 Aug 25
TI  - Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of
      the Advisory Committee on Immunization Practices - United States, 2017-18
      Influenza Season.
PG  - 1-20
LID - 10.15585/mmwr.rr6602a1 [doi]
AB  - This report updates the 2016-17 recommendations of the Advisory Committee on
      Immunization Practices (ACIP) regarding the use of seasonal influenza vaccines
      (MMWR Recomm Rep 2016;65[No. RR-5]). Routine annual influenza vaccination is
      recommended for all persons aged >/=6 months who do not have contraindications. A
      licensed, recommended, and age-appropriate vaccine should be used.For the 2017-18
      season, quadrivalent and trivalent influenza vaccines will be available.
      Inactivated influenza vaccines (IIVs) will be available in trivalent (IIV3) and
      quadrivalent (IIV4) formulations. Recombinant influenza vaccine (RIV) will be
      available in trivalent (RIV3) and quadrivalent (RIV4) formulations. Live
      attenuated influenza vaccine (LAIV4) is not recommended for use during the
      2017-18 season due to concerns about its effectiveness against (H1N1)pdm09
      viruses during the 2013-14 and 2015-16 seasons. Recommendations for different
      vaccine types and specific populations are discussed. No preferential
      recommendation is made for one influenza vaccine product over another for persons
      for whom more than one licensed, recommended product is available.Updates to the 
      recommendations described in this report reflect discussions during public
      meetings of ACIP held on October 20, 2016; February 22, 2017; and June 21, 2017. 
      New and updated information in this report includes the following:*Vaccine
      viruses included in the 2017-18 U.S. trivalent influenza vaccines will be an
      A/Michigan/45/2015 (H1N1)pdm09-like virus, an A/Hong Kong/4801/2014 (H3N2)-like
      virus, and a B/Brisbane/60/2008-like virus (Victoria lineage). Quadrivalent
      influenza vaccines will contain these three viruses and an additional influenza B
      vaccine virus, a B/Phuket/3073/2013-like virus (Yamagata lineage).* Information
      on recent licensures and labelling changes is discussed, including licensure of
      Afluria Quadrivalent (IIV4; Seqirus, Parkville, Victoria, Australia); Flublok
      Quadrivalent (RIV4; Protein Sciences, Meriden, Connecticut); and expansion of the
      age indication for FluLaval Quadrivalent (IIV4; ID Biomedical Corporation of
      Quebec, Quebec City, Quebec, Canada), previously licensed for >/=3 years, to >/=6
      months.* Pregnant women may receive any licensed, recommended, age-appropriate
      influenza vaccine.* Afluria (IIV3; Seqirus, Parkville, Victoria, Australia) may
      be used for persons aged >/=5 years, consistent with Food and Drug
      Administration-approved labeling.* FluMist Quadrivalent (LAIV4; MedImmune,
      Gaithersburg, Maryland) should not be used during the 2017-18 season due to
      concerns about its effectiveness against influenza A(H1N1)pdm09 viruses in the
      United States during the 2013-14 and 2015-16 influenza seasons.This report
      focuses on the recommendations for use of vaccines for the prevention and control
      of influenza during the 2017-18 season in the United States. A Background
      Document containing further information and a summary of these recommendations
      are available at
      https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html. These
      recommendations apply to licensed influenza vaccines used within Food and Drug
      Administration-licensed indications, including those licensed after the
      publication date of this report. Updates and other information are available at
      CDC's influenza website (https://www.cdc.gov/flu). Vaccination and health care
      providers should check CDC's influenza website periodically for additional
      information.
FAU - Grohskopf, Lisa A
AU  - Grohskopf LA
AD  - Influenza Division, National Center for Immunization and Respiratory Diseases,
      CDC.
FAU - Sokolow, Leslie Z
AU  - Sokolow LZ
AD  - Influenza Division, National Center for Immunization and Respiratory Diseases,
      CDC.
AD  - Battelle Memorial Institute, Atlanta, Georgia.
FAU - Broder, Karen R
AU  - Broder KR
AD  - Immunization Safety Office, National Center for Emerging and Zoonotic Infectious 
      Diseases, CDC.
FAU - Walter, Emmanuel B
AU  - Walter EB
AD  - Duke University School of Medicine, Durham, North Carolina.
FAU - Bresee, Joseph S
AU  - Bresee JS
AD  - Influenza Division, National Center for Immunization and Respiratory Diseases,
      CDC.
FAU - Fry, Alicia M
AU  - Fry AM
AD  - Influenza Division, National Center for Immunization and Respiratory Diseases,
      CDC.
FAU - Jernigan, Daniel B
AU  - Jernigan DB
AD  - Influenza Division, National Center for Immunization and Respiratory Diseases,
      CDC.
LA  - eng
PT  - Journal Article
PT  - Practice Guideline
DEP - 20170825
PL  - United States
TA  - MMWR Recomm Rep
JT  - MMWR. Recommendations and reports : Morbidity and mortality weekly report.
      Recommendations and reports
JID - 101124922
RN  - 0 (Influenza Vaccines)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Advisory Committees
MH  - Aged
MH  - Centers for Disease Control and Prevention (U.S.)
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Immunization Schedule
MH  - Infant
MH  - Influenza Vaccines/adverse effects/*therapeutic use
MH  - Influenza, Human/epidemiology/*prevention & control
MH  - Male
MH  - Middle Aged
MH  - Pregnancy
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Seasons
MH  - United States/epidemiology
MH  - Young Adult
EDAT- 2017/08/26 06:00
MHDA- 2017/08/29 06:00
CRDT- 2017/08/26 06:00
AID - 10.15585/mmwr.rr6602a1 [doi]
PST - epublish
SO  - MMWR Recomm Rep. 2017 Aug 25;66(2):1-20. doi: 10.15585/mmwr.rr6602a1.